![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CLSTN2 |
Gene summary for CLSTN2 |
![]() |
Gene information | Species | Human | Gene symbol | CLSTN2 | Gene ID | 64084 |
Gene name | calsyntenin 2 | |
Gene Alias | ALC-GAMMA | |
Cytomap | 3q23 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q9H4D0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64084 | CLSTN2 | S014 | Human | Liver | HCC | 6.80e-12 | 5.15e-01 | 0.2254 |
64084 | CLSTN2 | S015 | Human | Liver | HCC | 9.93e-07 | 4.33e-01 | 0.2375 |
64084 | CLSTN2 | S016 | Human | Liver | HCC | 1.36e-20 | 5.89e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CLSTN2 | SNV | Missense_Mutation | c.2659N>T | p.Pro887Ser | p.P887S | Q9H4D0 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-38-4625-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CLSTN2 | SNV | Missense_Mutation | c.2212N>T | p.Gly738Cys | p.G738C | Q9H4D0 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-38-4632-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | gemcitabine | PD | |
CLSTN2 | SNV | Missense_Mutation | c.362N>A | p.Thr121Lys | p.T121K | Q9H4D0 | protein_coding | tolerated(0.18) | possibly_damaging(0.895) | TCGA-49-6743-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD | |
CLSTN2 | SNV | Missense_Mutation | c.1362N>T | p.Trp454Cys | p.W454C | Q9H4D0 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-49-6743-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD | |
CLSTN2 | SNV | Missense_Mutation | c.1303N>A | p.Asp435Asn | p.D435N | Q9H4D0 | protein_coding | deleterious(0.02) | possibly_damaging(0.767) | TCGA-49-AARN-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CLSTN2 | SNV | Missense_Mutation | novel | c.853C>A | p.Leu285Met | p.L285M | Q9H4D0 | protein_coding | deleterious(0) | possibly_damaging(0.855) | TCGA-55-6970-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
CLSTN2 | SNV | Missense_Mutation | novel | c.1039N>A | p.Leu347Met | p.L347M | Q9H4D0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-55-7907-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CLSTN2 | SNV | Missense_Mutation | novel | c.2554N>T | p.Val852Leu | p.V852L | Q9H4D0 | protein_coding | tolerated(0.07) | benign(0.123) | TCGA-55-7907-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CLSTN2 | SNV | Missense_Mutation | c.1339G>C | p.Asp447His | p.D447H | Q9H4D0 | protein_coding | deleterious(0.04) | possibly_damaging(0.77) | TCGA-55-7994-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | CR | |
CLSTN2 | SNV | Missense_Mutation | novel | c.2332T>A | p.Tyr778Asn | p.Y778N | Q9H4D0 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-55-8508-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |